Deep-pocketed investors have adopted a bearish approach towards Avadel Pharmaceuticals AVDL, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AVDL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Avadel Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 0% leaning bullish and 100% bearish. Among these notable options, 6 are puts, totaling $229,970, and 5 are calls, amounting to $181,540.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $15.0 for Avadel Pharmaceuticals over the last 3 months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Avadel Pharmaceuticals stands at 28.0, with a total volume reaching 10,712.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Avadel Pharmaceuticals, situated within the strike price corridor from $15.0 to $15.0, throughout the last 30 days.
Avadel Pharmaceuticals Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AVDL | PUT | TRADE | BEARISH | 01/16/26 | $4.0 | $3.7 | $4.0 | $15.00 | $39.6K | 11 | 844 |
| AVDL | PUT | TRADE | BEARISH | 01/16/26 | $4.0 | $3.7 | $4.0 | $15.00 | $39.2K | 11 | 1.0K |
| AVDL | PUT | TRADE | BEARISH | 01/16/26 | $3.9 | $3.7 | $3.9 | $15.00 | $38.6K | 11 | 1.6K |
| AVDL | PUT | TRADE | BEARISH | 01/16/26 | $3.9 | $3.7 | $3.9 | $15.00 | $38.6K | 11 | 1.2K |
| AVDL | PUT | TRADE | BEARISH | 01/16/26 | $3.9 | $3.7 | $3.9 | $15.00 | $38.6K | 11 | 1.2K |
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
After a thorough review of the options trading surrounding Avadel Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Avadel Pharmaceuticals Standing Right Now?
- Trading volume stands at 206,760, with AVDL's price down by -0.84%, positioned at $14.17.
- RSI indicators show the stock to be may be approaching oversold.
- Earnings announcement expected in 42 days.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Avadel Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
